Next Generation Therapeutics forHuman Repair and Regeneration
FORWARD LOOKING STAEMENTS AND DISCLAIMER OF RISKS AND UNCERTAINTIESSome of the statements contained and incorporated in th...
About Bioquark Inc.• Biopharmaceutical company• Lead biologic candidate - BQ-A• Regeneration and repair of organs and  tis...
Bioquark Inc. - Financing Seed money - US $750K Currently raising:  - US $1MM via Reg D 504 private placement  - US $20M...
Market Opportunity   Global Healthcare - OECD est. 2012 - >$6 TrillionCellular Degeneration              Cellular Damage  ...
Humans Have Very LimitedRegenerative and Repair Capacity
Organ Transplantation / Replacement- Worldwide >$350B / yr (inc. dialysis, CRM, stents, anti-rejection drugs)- Host versus...
Pharmaceuticals Don’t Reverse Damage                                        Direct     Substance                          ...
Stem Cells???                         Technical / Strategic Issues                                      Plasticity        ...
Clues From Nature
Epimorphosis   Damage                                  De-differentiation                                                 ...
Oocyte - Biological Re-Start                                MorphogenesisNuclear DNA Repair                               ...
Microenvironment Centric  Embryo                           Blastema                 Introducing               foreign tiss...
BQ-A – Standardized Ooplasm Factors                  FDA                  - Regulated under PHS Act                  - Pol...
Heterogeneous Drugs
BQ-A - Melanoma Model
BQ-A - Melanoma Tumor Invasiveness             Bio-Marker Expression                              COX-2 ExpressionNon-trea...
BQ-A - TBI Model                       Brain Gross AnatomyControl (No TBI)           14 days after TBI         BQ-A treatm...
BQ-A - TBI Model -   Morris Water Navigation TaskTesting hippocampus impaired spatial learning and memory
BQ-A - Derm ApplicationsSqualene Monohydroperoxide  Induced Wrinkling Model
BQ-A - Derm Applications      Alopecia Model
BQ-A – Mouse Gerontology                           Initiate                           chronic                            d...
1st Clinical Target - Kidney- NIDDK - 2007 - >500K Americans suffer from End-Stage Renal Disease(ESRD)- > 111K new cases d...
BQ-A - FSGS Development Plan- Repair and regenerate podocytes- Induce clinical remission - as measured by reduction inprot...
Partnering Strategy- Organ Specific Development- Generate later stage clinical data- License to specialty pharma along spe...
BQ-A - Intellectual Property Protection              Much more than typical drug- Patents      Composition      Use      M...
BQ-A - Strategic Positioning       Therapy      Global Costs               Regeneration                      RepairOrgan T...
Thank You     Ira S. Pastor  CEO, Bioquark Inc.pastor@bioquark.com
Upcoming SlideShare
Loading in …5
×

Bioquark Rodman & Renshaw Presentation 2012

708 views

Published on

Bioquark, Inc., (www.bioquark.com) a biopharmaceutical company engaged in the development of proprietary biological drugs that can be simultaneously leveraged for both the regeneration and repair of human organs and tissues, CEO, Ira S. Pastor, presenting the Company’s overview at the Rodman and Renshaw Annual Global Investment Conference’s (14th Annual Healthcare Conference) on Thursday, September 11, 2012, at 10:00 a.m. Eastern time at the Waldorf Astoria Hotel in New York City.

Published in: Business
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
708
On SlideShare
0
From Embeds
0
Number of Embeds
4
Actions
Shares
0
Downloads
8
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Bioquark Rodman & Renshaw Presentation 2012

  1. 1. Next Generation Therapeutics forHuman Repair and Regeneration
  2. 2. FORWARD LOOKING STAEMENTS AND DISCLAIMER OF RISKS AND UNCERTAINTIESSome of the statements contained and incorporated in this presentation are forward-lookingstatements within the meaning of Section 27A of the Securities Act and Section 21E of theExchange Act. Such statements are based upon the current beliefs and expectations ofBioquark Inc.’s management as of the time the presentation is made and are subject tosignificant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Forward statements can be identified by the fact that they do not relatestrictly to historical or current facts. Investors and the public are cautioned not to place unduereliance on these forward-looking statements, which speak only to the date such data waspresented. Examples include statements of anticipated needs of patients, our ability toaddress those needs, and projected future gains for investors.Bioquark Inc. undertakes no obligation to publicly revise these forward-looking statements toreflect events or circumstances that arise after the presentation of this information, whetheras a result of new information, subsequent events or otherwise.The following factors, among others, could cause actual results to differ from those set forth inthe forward-looking statements: increased competition; increased costs; changes in generalmarket conditions; changes in industry trends; changes in the regulatory environment;changes in technology; changes in the Bioquark Inc.’s plans, initiatives and strategies.
  3. 3. About Bioquark Inc.• Biopharmaceutical company• Lead biologic candidate - BQ-A• Regeneration and repair of organs and tissues• Incorporated in May 2008• Delaware C-Corp• Central Laboratory – Tampa, FL
  4. 4. Bioquark Inc. - Financing Seed money - US $750K Currently raising: - US $1MM via Reg D 504 private placement - US $20MM via self-registered public offering to: - pre-clinical development of BQ-A - BQ-A manufacturing scale-up (CMC) - BQ-A clinical data of in FSGS Major investor value inflection in 3 years Capitalize on short term opportunities in derma- cosmetic and companion animal health
  5. 5. Market Opportunity Global Healthcare - OECD est. 2012 - >$6 TrillionCellular Degeneration Cellular Damage Alzheimer’s Auto-immune CHF Cancer Parkinson’s Chronic Inflammation Type I Diabetes etc. etc.
  6. 6. Humans Have Very LimitedRegenerative and Repair Capacity
  7. 7. Organ Transplantation / Replacement- Worldwide >$350B / yr (inc. dialysis, CRM, stents, anti-rejection drugs)- Host versus graft reaction- Major donor / recipient imbalance Annual Deaths from People Waiting Annual # of Organ Organ Failure For a Transplant Transplants Heart 874,000 2,900 2,200 Lung 159,000 2,000 1,500 Kidney 44,000 86,000 17,000 Pancreas 32,000 1,600 500 Liver 28,000 17,000 6,500 Intestine 1,200 300 200 Bladder 15,000 N/A N/A Total 1,153,200 109,800 27,900
  8. 8. Pharmaceuticals Don’t Reverse Damage Direct Substance Killing Replacement Receptor Transporter Interaction Interaction Enzyme Interaction
  9. 9. Stem Cells??? Technical / Strategic Issues Plasticity Genomic Instability Stress Induced Apoptosis Senescence Heteroplasmy Minimal Tumorigenicity Successful Immunogenicity Infection Outcomes Tissue homeostasis To Date- Embryonic Engraftment- Adult Paracrine Inhibition- Fetal Survivability- Induced Pluripotent Positional Identity- Cord Size Control- Parthenogenic Shape- etc. 3D Patterning
  10. 10. Clues From Nature
  11. 11. Epimorphosis Damage De-differentiation Proliferation ReprogrammingSize / Positional Morphogenesis Specification Re-differentiation Tissue Organization Re-Integration
  12. 12. Oocyte - Biological Re-Start MorphogenesisNuclear DNA Repair Epigenetic Modifications Telomere Control Mitochondrial DNA Repair Infectious / Oxidative / Microenvironment Inflammatory Defense Regulation Organelle Remodeling
  13. 13. Microenvironment Centric Embryo Blastema Introducing foreign tissues such as: - Stem Cells - Somatic Cells - Cancer CellsNormal Fetus Abnormal Normal Limb
  14. 14. BQ-A – Standardized Ooplasm Factors FDA - Regulated under PHS Act - Polypeptide/carbohydrate based - Extracted from living organism - Complex physiochemical structure - Less well defined than NCE - Mfg process defines product EMEA - produced by or extracted from a biological source - combination of physico-chemical- biological testing - production process and its control is needed for its characterization and the determination of its quality
  15. 15. Heterogeneous Drugs
  16. 16. BQ-A - Melanoma Model
  17. 17. BQ-A - Melanoma Tumor Invasiveness Bio-Marker Expression COX-2 ExpressionNon-treated BQ-A (7 days) BQ-A (14 days) BQ-A (21 days) Control i-NOS ExpressionNon-treated BQ-A (7 days) BQ-A (14 days) BQ-A (21 days) Control
  18. 18. BQ-A - TBI Model Brain Gross AnatomyControl (No TBI) 14 days after TBI BQ-A treatment 14d β-amyloid Immuno-histochemistry
  19. 19. BQ-A - TBI Model - Morris Water Navigation TaskTesting hippocampus impaired spatial learning and memory
  20. 20. BQ-A - Derm ApplicationsSqualene Monohydroperoxide Induced Wrinkling Model
  21. 21. BQ-A - Derm Applications Alopecia Model
  22. 22. BQ-A – Mouse Gerontology Initiate chronic dosing N=10 N=10
  23. 23. 1st Clinical Target - Kidney- NIDDK - 2007 - >500K Americans suffer from End-Stage Renal Disease(ESRD)- > 111K new cases diagnosed – 90K deaths annually- > $30 billion in care – 370K on dialysis – 17K kidney transplants- FSGS indication offers: - rapid proof-of-concept - FDA Subpart E - orphan disease classification benefits
  24. 24. BQ-A - FSGS Development Plan- Repair and regenerate podocytes- Induce clinical remission - as measured by reduction inproteinuria2012 2013 2014 2015 2016
  25. 25. Partnering Strategy- Organ Specific Development- Generate later stage clinical data- License to specialty pharma along specific “organ verticals”- Keep eye on tangential opportunistic markets / spin-outs (derma-cosmetic; companion animal health)
  26. 26. BQ-A - Intellectual Property Protection Much more than typical drug- Patents Composition Use MOA Production Genetic variety- Industrial Scale Biologic Manufacturing Trade Secrets- Heterogeneous Bioequivalence Barrier (i.e. Premarin- style multiple decade exclusivity) Generic competition highly unlikely
  27. 27. BQ-A - Strategic Positioning Therapy Global Costs Regeneration RepairOrgan Transplant / ~$300 Billion - Host vs. Graft Reaction N/AReplacement - Insufficient Supplies - CostPharmaceuticals / ~$600 Billion - Limited to conditions where single - Cannot reverseGrowth Factors growth factor predominates (EPO, genetic damage GM-CSF, BMP) once it has occurredStem Cells / Cell ~$4 Billion - Technical problems - Effects limitedTherapy - Regulatory to trophic - Cost support - CostBQ-A N/A - Provides dual solution in reprogramming tissues for both tissue regeneration and repair - Administered via traditional biopharma delivery vehicles - Regulated as biologic by both FDA and EMEA - Cost effective
  28. 28. Thank You Ira S. Pastor CEO, Bioquark Inc.pastor@bioquark.com

×